tbuckley/cabot-search huggingface dataset:
Comparison of the <i>KRAS/EGFR </i>mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.
Authors: Anna M. Varghese, Camelia S. Sima, Jamie E. Chaft, Melissa Lynne Johnson, Yelena Yuriy Janjigian, Alexander Edward Dela Cruz Drilon, Helena Alexandra Yu, Gregory J. Riely, Marc Ladanyi, Mark G. Kris
Journal: Journal of Clinical Oncology (2012)

7580 Background: In practice, we encounter patients (pts) with lung cancers who state they smoked only while in college. The impact of this degree of tobacco use on cancer biology is unknown. We have shown that EGFR mutations are less common in pts who smoked &gt; 15 pack years (PY). We hypothesize that among pts with lung cancer the KRAS / EGFR mutation profile and overall survival (OS) of “collegiate smokers” (former smokers who smoked between 101 lifetime cigarettes and 5 PY) will be distinct from never smokers and former smokers with ≥ 15 PY. Methods: We collected age, sex, stage, and survival for pts evaluated from 2004 - 2009 with stage IIIB/IV lung cancer with known KRAS and EGFR status. ALK testing was not available routinely during this time. Smoking history was obtained using a patient completed survey. The Fisher exact test was used to compare mutation profiles. The log rank test was used to compare OS. Results: Smoking history and clinical data were available for 852 pts with Stage IIIB/IV lung cancer with known KRAS and EGFR status: 307 never smokers, 178 current smokers, and 367 former smokers. Of the former smokers, 55 were “collegiate smokers”, 61 had smoked 5-15 PY, and 251 had smoked ≥ 15 PY. The KRAS / EGFR mutation profiles by smoking history are shown below (Table). The KRAS / EGFR mutation profile of “collegiate smokers” is distinct from those of pts who were never smokers (p &lt; .001) and former smokers with ≥ 15 PY (p &lt; .001) but similar to that of pts who were former smokers with 5-15 PY (p = 0.9). Median OS after diagnosis of stage IIIB/IV lung cancer for “collegiate smokers” was 25 months (mos), compared to 32 mos for never smokers (p = 0.4) and 21 mos for former smokers with ≥ 15 PY (p = 0.63). Conclusions: “Collegiate smokers” are a distinct group of pts with a higher incidence of KRAS mutations and lower incidence of EGFR mutations compared to never smokers. These data suggest that even a small amount of cigarette smoking influences the biology of lung cancer. These findings reinforce the importance of doing mutation testing routinely for all pts with lung cancer to guide clinical care. [Table: see text]
Quality of Life in Adolescents and Adults with Thalassemia: A Report of the Thalassemia Longitudinal Cohort.
Authors: Amy Sobota, Robert Yamashita, Yan Xu, Felicia Trachtenberg, Dorothy A. Kleinert, Patricia J Giardina, Janet L Kwiatkowski, Dru Foote, Vivekanandan Thayalasuthan, John B Porter, Alexis A. Thompson, Leann Schilling, Charles T. Quinn, Ellis J Neufeld
Journal: Blood (2009)
Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).
Authors: Yulia Lin, Helene Bruyere, Douglas E. Horsman, Michael J. Barnett, Donna E. Hogge, Thomas J. Nevill, Stephen H. Nantel, Heather J. Sutherland, Cynthia L. Toze, John D. Shepherd, Julye C. Lavoie, Kevin W. Song, Clayton A. Smith, Donna L. Forrest
Journal: Blood (2004)
MicroRNA Biomarkers and Platelet Reactivity
Authors: Nicholas Sunderland, Philipp Skroblin, Temo Barwari, Rachael P. Huntley, Ruifang Lu, Abhishek Joshi, Ruth C. Lovering, Manuel Mayr
Journal: Circulation Research (2017)

Over the last few years, several groups have evaluated the potential of microRNAs (miRNAs) as biomarkers for cardiometabolic disease. In this review, we discuss the emerging literature on the role of miRNAs and other small noncoding RNAs in platelets and in the circulation, and the potential use of miRNAs as biomarkers for platelet activation. Platelets are a major source of miRNAs, YRNAs, and circular RNAs. By harnessing multiomics approaches, we may gain valuable insights into their potential function. Because not all miRNAs are detectable in the circulation, we also created a gene ontology annotation for circulating miRNAs using the gene ontology term extracellular space as part of blood plasma. Finally, we share key insights for measuring circulating miRNAs. We propose ways to standardize miRNA measurements, in particular by using platelet-poor plasma to avoid confounding caused by residual platelets in plasma or by adding RNase inhibitors to serum to reduce degradation. This should enhance comparability of miRNA measurements across different cohorts. We provide recommendations for future miRNA biomarker studies, emphasizing the need for accurate interpretation within a biological and methodological context.
AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.
Authors: Gary Calandra, John McCarty, Joseph McGuirk, Bart Barlogie, Sue-Anne Crocker, Karin Badel
Journal: Blood (2006)
Histone Deacetylation Makes an Important Contribution to Chromatin Condensation and Enucleation during Murine Erythroblast Terminal Differentiation.
Authors: Sharon Wald Krauss, Evgenya Popova, Sarah A. Short, Gloria Lee, Jonathan Villalobos, Mark J. Koury, Sergei Grigoryev, Joel Anne Chasis
Journal: Blood (2006)
PTU-160 Dedicated Barrett’s Oesophagus Surveillance Lists Improves Diagnosis and Documentation of Findings
Authors: S Phillpotts, T El Menabawey, R Preedy, K Besherdas
Journal: Gut (2016)

<h3>Introduction</h3> Oesophageal cancer is the fifth commonest cause of cancer death in the UK, and the incidence of adenocarcinoma is rising. Patients are often without symptoms until the tumour has grown to be inoperable, and the survival for this cancer remains poor. Early diagnosis is crucial to improve survival. Barrett’s oesophagus is the pre-cancerous lesion. The British Society of Gastroenterology (BSG) recommends regular surveillance depending on endoscopic and histological findings in order to identify oesophageal cancers at an earlier stage, therefore reducing mortality. There is evidence from previous studies on Barrett’s highlighting poor adherence to surveillance intervals, documentation of Barrett’s length as well as biopsy protocol. Pooling of Barrett’s patients on dedicated Barrett’s lists may help with better adherence to guidelines and may enhance detection of dysplasia with better outcomes for patients. We aim to investigate whether a ‘dedicated’ Barrett’s surveillance list improved diagnosis and adherence to the BSG guidelines compared to more ‘ad-hoc’ surveillance on routine lists. <h3>Methods</h3> This retrospective study analysed all patients undergoing endoscopy for Barrett’s surveillance at a North London hospital over a one-year period. We looked at documentation of the Prague Classification; adherence to the Seattle Protocol; exclusion of Barrett’s; biopsy results; and follow up. <h3>Results</h3> 76 patients underwent surveillance, with 42 (55%) being performed during the 7 dedicated lists. The dedicated list excluded Barrett’s at endoscopy in 7 cases (9.2%) compared to only 1 (1.3%) in the routine list. Documentation was also significantly better with 85% of patients having the Prague Classification recorded, compared to only 32% in the routine group (p &lt; 0.001). Also notable are the 7 patients in the routine group that had missing or erroneous information relating to the Seattle protocol. Adherence to the Seattle protocol was equally poor in both groups (dedicated = 49%, routine = 58%). There was no difference in histology results between the 2 groups. The follow up showed no correlation with the initial list, and frequently didn’t adhere to the BSG guidance. <h3>Conclusion</h3> We provide evidence that dedicated lists improve both diagnosis and documentation in patients attending for Barrett’s surveillance. However, there still appears to be considerable scope for improving adherence to biopsy protocols and follow up plans. The proven benefit of dedicated endoscopic lists could be extended to dedicated follow up clinics to better subsequent management. Despite the stated shortcomings we recommend trials of dedicated lists on a wider scale to investigate whether this has a definite improvement in patient experience and management. <h3>Disclosure of Interest</h3> None Declared
Chemical Mutagenesis Screen Identifies Novel Drug Resistant JAK2 Variants in V617FJAK2 Mediated MPN and Predict HSP90 Inhibitors As Possible Agents to Overcome Drug Resistance
Authors: Sivahari Prasad Gorantla, Detlef Bentrop, Nikolas Bubnoff, Anna Lena Illert, Robert Zeiser, Justus Duyster
Journal: Blood (2015)
Poor Survival Predicted by MDM2 Oncoprotein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Wild-Type TP53 Gene
Authors: Gabrielle L. Rocque, Michael B. Møller, Gisele W. B. Colleoni, Margarita Sánchez-Beato, Tina M. Green, Trine Thorborg, Miguel A. Piris, Jens C. Eickhoff, Matthew Twohig, Jeffrey T. Malik, Allen H. Young, Terry D. Oberley, James S. Malter, Judith Ferry, Wing C. Chan, Dennis D. Weisenburger, Timothy C. Greiner, Ken H. Young
Journal: Blood (2008)
Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response
Authors: Zuolin Ying, Madeleine Duvic, Lisa Shiue, Timothy Langridge, Meghali Goswami, Xiao Ni
Journal: Blood (2015)
ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia
Authors: Fei Yang, Franklin Moore, Dean Westberry, Miriam Hough, Julie Partain, William H Fleming, Tibor Kovacsovics, Richard D. Press
Journal: Blood (2011)
Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India
Authors: Fouzia NA, Revathi Raj, Dharma Choudhary, Sharat Damodar, Shashikant Apte, M Joseph John, Ashish Dixit, Kannan Subramanyan, Jose Easow, Sunil Bhat, Chepsy C Philip, Amrith Mathew, Kavitha M Lakshmi, Anu Korula, Aby Abraham, Auro Viswabandya, Alok Srivastava
Journal: Blood (2015)
Pegfilgrastim Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay.
Authors: Neil Phillips, Anand Lokare, Kathy Holder, Sridhar Chaganti, Richard Lovell, Shankaranarayana Paneesha, Donald Milligan
Journal: Blood (2009)
Milestones of Post Transplant Monitoring of JAK2 p.V617F Positive MPN Patients.
Authors: Thoralf Lange, Anja Edelmann, Uwe Siebolts, Claudia Nehring, Nadja Jäckel, Michael Cross, Maier Jacqueline, Dietger Niederwieser, Claudia Wickenhauser
Journal: Blood (2010)
Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.
Authors: Marcos De Lima, X. Wang, P.F. Thall, D. Couriel, R.B. Jones, E.J. Shpall, U. Popat, S. Giralt, M. Korbling, R. Champlin, B.S. Andersson
Journal: Blood (2006)
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.
Authors: Philip L. McCarthy, Kouros Owzar, Edward A. Stadtmauer, Sergio Giralt, David D Hurd, Hani Hassoun, Craig Hofmeister, Paul Richardson, Daniel J. Weisdorf, Marcelo C. Pasquini, Vera Hars, Michael Kelly, John Postiglione, Susan Sutherland, Kenneth C. Anderson, Charles Linker
Journal: Blood (2009)
Clinical Guidelines for Management of Acne Vulgaris—Reply
Authors: Carly J. Roman, Adam S. Cifu, Sarah L. Stein
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Carboxypeptidase M Cleaves the C-Terminal Lysine of Stromal Cell-Derived Factor-1α and Is Expressed by Human Bone Marrow Cells.
Authors: Leah A. Marquez-Curtis, Kathleen Deiteren, Lambeir Anne-Marie, Ali Jalili, Neeta Shirvaikar, Anna Janowska-Wieczorek
Journal: Blood (2006)
Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424
Authors: Srdan Verstovsek, Hagop M. Kantarjian, Animesh D. Pardanani, Timothy Burn, Kris Vaddi, John Redman, Edward C Bradley, Richard Levy, Steven Friedman, Gregory Hollis, Ayalew Tefferi
Journal: Blood (2008)
Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2
Authors: Amitha Domalpally, Traci E. Clemons, Ronald P. Danis, SriniVas R. Sadda, Catherine A. Cukras, Cynthia A. Toth, Thomas R. Friberg, Emily Y. Chew
Journal: Ophthalmology (2017)
NHS crisis: where should any new money be spent?
Authors: Zosia Kmietowicz, Gareth Iacobucci, Abi Rimmer
Journal: BMJ (2017)

Until 2014 the NHS in England was given emergency funding to cover extra demand on services over winter. However, seen as a “panic measure” that came too late in the year to be used properly, it was scrapped in 2014. Instead NHS England has for the past three years built the £400m annual payment into local allocations up front. Despite the NHS experiencing its worst crisis in 15 years, Theresa May has been steadfast in her refusal to pump extra money into the system. Simon Stevens, NHS England’s chief executive, has been saying for some time that he would put any extra funding available into social care. 

The BMJ asked doctors, managers, and council representatives where they would put money from a winter pressure cash injection.

“Invest any additional monies in community, mental health, and social care services, which as a statement coming from an acute care trust chief executive might seem slightly odd. However, specific targeted money to reduce the numbers of patients taking up beds who could be looked after elsewhere is, in my view, critical to taking the pressure off the acute service.” …
Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide.
Authors: Esther Natalie Oliva, Francesco Nobile, Pasquale Iacopino, Giuliana Alimena, Francesco Di Raimondo, Giuseppe A Palumbo, Carmelo Laganà, Maria Grazia D'Errigo, Roberto Latagliata, Maria Cuzzola
Journal: Blood (2010)
Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy.
Authors: Michail Ignatiadis, Gert G. Van den Eynden, Roberto Salgado, Marco Fornili, Christine Desmedt, Esther Holgado, V. A. McNally, Astrid Christina Kiermaier, Javier Cortes, Andreas Schneeweiss, Karen Willard-Gallo, Elia Biganzoli, Christos Sotiriou
Journal: Journal of Clinical Oncology (2016)

11507 Background: There are no data about the association between the presence of tumor infiltrating lymphocytes (TILs) at surgery after dual HER2 blockade-based preoperative treatment and pathological complete response (pCR). Methods: Stromal TILs (sTILs) before (at baseline) and after (at surgery) dual HER2 blockade were evaluated in 225 patients enrolled in the Tryphaena study. sTILs percentage (%) was computed as the mean of 2 independent reviewers who scored TILs according to consensus guidelines (Ann Oncol 2014). Tryphaena is a phase 2 trial that randomized patients with HER2-amplified breast cancer to trastuzumab (H) / pertuzumab (P) concurrently or sequentially with an anthracycline containing regimen (3FEC+HPx3->Docetaxel+HPx3 or FECx3->Docetaxel+HPx3) or concurrently with an anthracycline-free regimen (Docetaxel/Carboplatin+HPx6) to establish safety. Associations between log sTILs (%) as continuous variable at baseline and at surgery with pCR defined as ypT0/is ypN0 were evaluated using linear regression models with and without adjustment for clinicopathological variables including age, histology grade, ER status, disease stage and treatment arm. Results: Among the 225 patients,131 (58.2%) achieved pCR. Increased log sTILs (%) at baseline were associated with increased probability of pCR (Coefficient Estimate, CE: 0.31, 95% Confidence Intervals, CI 0.03, 0.59, p=0.03) in univariate analysis and there was a trend for an association after adjustment for clinicopathological characteristics (CE: 0.30, 95%CI: -0.05, 0.64, p=0.09). Interestingly, increased log sTILs (%) at surgery (N=140 patients for whom tumor bed was identified) were associated with lower probability of pCR in univariate analysis (CE: -0.44, 95% CI -0.75, -0.13, p=0.006) but also after adjustment for clinicopathological variables (CE: -0.60, 95%CI: -1.00, -0.20, p=0.0004). Conclusions: Patients with HER2-amplified breast cancer that did not achieve pCR after dual HER2 blockade-based regimens had lower TILs at baseline but higher TILs at surgery compared with pCR patients. These results might have implications for the development of immune checkpoint inhibitors in these patients.
167P Association of CHFR and WRN promotor methylation and clinical benefit from irinotecan-based chemotherapy for metastatic colorectal cancer
Authors: S.Y. Kim, S.M. Dong, H.Y. Yeo, J.Y. Baek, E.K. Shim, J.Y. Ku, H.J. Chang
Journal: Annals of Oncology (2015)
Prurigo Pigmentosa in White Monozygotic Twins
Authors: Carine Houriet, Delphine L. Perruchoud, Helmut Beltraminelli, Luca Borradori
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.
Authors: Marek Trneny, David Belada, Ingrid Vasova, Robert Pytlik, Tomas Kozak, Alice Sykorova, Katerina Kubackova, Jan Pirnos, Ingrid Bolomska, Marketa Petrova
Journal: Blood (2005)
Natalizumab Increases Circulating CD34+ Cells with An Impaired Functional Potential In Patients with Multiple Sclerosis without Affecting the Bone Marrow.
Authors: Christian Saure, Fabian Zohren, Thomas Schroeder, Ingmar Bruns, Ron Patrick Cadeddu, Ute Fischer, Guido Kobbe, Hans Peter Hartung, Bernd C Kieseier, Rainer Haas
Journal: Blood (2010)
Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
Authors: Jesus San Miguel, Vania TM Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae-Hoon Lee, Hermann Einsele, Hans Salwender, Monika Sopala, Suman Redhu, Sofia Paul, Claudia Corrado, Florence Binlich, Paul G. Richardson
Journal: Blood (2014)
Motor Learning Requires Purkinje Cell Synaptic Potentiation through Activation of AMPA-Receptor Subunit GluA3
Authors: Nicolas Gutierrez-Castellanos, Carla M. Da Silva-Matos, Kuikui Zhou, Cathrin B. Canto, Maria C. Renner, Linda M.C. Koene, Ozgecan Ozyildirim, Rolf Sprengel, Helmut W. Kessels, Chris I. De Zeeuw
Journal: Neuron (2017)
the miR-99∼125 Polycistrons Promote Leukemogenesis in a Cell-Context Dependent Manner by Shifting the Balance Between TGFβ- and Wnt-Signaling
Authors: Stephan Emmrich, Mareike Rasche, Jennifer Schöning, Zhe Li, Axel Schambach, Dirk Reinhardt, Jan-Henning Klusmann
Journal: Blood (2012)
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.
Authors: Nicola Esposito, Fabrizio Quarantelli, Luigia Luciano, Barbara Izzo, Anna Lucia Peluso, Marco Picardi, Susan Branford, D.L. White, Timothy Hughes, Jerald Radich, Simona Soverini, Ilaria Iacobucci, Giuseppe Saglio, Thea Kalebic, Mark Thornquist, Giovanni Martinelli, Fabrizio Pane
Journal: Blood (2008)
Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?
Authors: Corrado Tarella, Alessandra Risso, Tiziana Spatola, Marco Ruella, Giuseppe Milone, Pietro Pioltelli, Anna Paola Iori, Paolo Di Bartolomeo, Alessandro Rambaldi, Andrea P Bacigalupo, William Arcese
Journal: Blood (2012)
Hemochromatois-Associated Gene Mutations in Patients with Myelodysplastic Syndromes with Refractory Anemia and Ringed Sideroblasts.
Authors: Zachary P. Nearman, Bianca Serio, Hadrian Szpurka, Ilka Warshawsky, Alan Lichtin, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2006)